ECSP23091202A - Moduladores de trex1 - Google Patents

Moduladores de trex1

Info

Publication number
ECSP23091202A
ECSP23091202A ECSENADI202391202A ECDI202391202A ECSP23091202A EC SP23091202 A ECSP23091202 A EC SP23091202A EC SENADI202391202 A ECSENADI202391202 A EC SENADI202391202A EC DI202391202 A ECDI202391202 A EC DI202391202A EC SP23091202 A ECSP23091202 A EC SP23091202A
Authority
EC
Ecuador
Prior art keywords
trex1
modulators
compositions
treating
compounds
Prior art date
Application number
ECSENADI202391202A
Other languages
English (en)
Inventor
Jonathan Wilson
Julian Levell
Aaron Coffin
Avinash Khanna
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of ECSP23091202A publication Critical patent/ECSP23091202A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Amplifiers (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proveen compuestos de fórmula (I): y sales farmacéuticamente aceptables y composiciones de los mismos, que son útiles para tratar una variedad de afecciones asociadas a TREX1.
ECSENADI202391202A 2021-05-05 2023-12-05 Moduladores de trex1 ECSP23091202A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163184460P 2021-05-05 2021-05-05

Publications (1)

Publication Number Publication Date
ECSP23091202A true ECSP23091202A (es) 2024-03-01

Family

ID=82016366

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202391202A ECSP23091202A (es) 2021-05-05 2023-12-05 Moduladores de trex1

Country Status (20)

Country Link
US (1) US20240262814A1 (es)
EP (1) EP4333985B1 (es)
JP (1) JP2024516289A (es)
KR (1) KR20240035385A (es)
CN (1) CN117561251A (es)
AU (1) AU2022269596A1 (es)
BR (1) BR112023022917A2 (es)
CA (1) CA3217421A1 (es)
CL (1) CL2023003253A1 (es)
CO (1) CO2023016367A2 (es)
CR (1) CR20230569A (es)
DO (1) DOP2023000241A (es)
EC (1) ECSP23091202A (es)
ES (1) ES3049639T3 (es)
IL (1) IL308220A (es)
JO (1) JOP20230275A1 (es)
MX (1) MX2023013045A (es)
PE (1) PE20241334A1 (es)
PH (1) PH12023553004A1 (es)
WO (1) WO2022235725A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151567A1 (en) * 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza
HK1211289A1 (en) * 2012-08-06 2016-05-20 Savira Pharmaceuticals Gmbh Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
KR20210102310A (ko) * 2018-12-06 2021-08-19 콘스텔레이션 파마슈티칼스, 인크. Trex1의 조절인자
EP4003985A1 (en) * 2019-07-23 2022-06-01 Constellation Pharmaceuticals, Inc. Modulators of trex1

Also Published As

Publication number Publication date
JOP20230275A1 (ar) 2023-11-02
ES3049639T3 (en) 2025-12-17
IL308220A (en) 2024-01-01
EP4333985B1 (en) 2025-07-30
KR20240035385A (ko) 2024-03-15
JP2024516289A (ja) 2024-04-12
CN117561251A (zh) 2024-02-13
MX2023013045A (es) 2024-01-19
DOP2023000241A (es) 2024-02-29
CL2023003253A1 (es) 2024-05-03
US20240262814A1 (en) 2024-08-08
WO2022235725A1 (en) 2022-11-10
PE20241334A1 (es) 2024-07-03
CA3217421A1 (en) 2022-11-10
PH12023553004A1 (en) 2024-03-11
CR20230569A (es) 2024-01-22
EP4333985A1 (en) 2024-03-13
AU2022269596A1 (en) 2023-11-16
BR112023022917A2 (pt) 2024-01-23
CO2023016367A2 (es) 2024-02-05

Similar Documents

Publication Publication Date Title
MX2024012029A (es) Moduladores del transductor de señal y activador de la transcripción y usos de los mismos
CL2021001461A1 (es) Moduladores de trex1
CO2024010861A2 (es) Moduladores stat y usos de los mismos
MX2024009943A (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
CL2024001346A1 (es) Agonistas inversos del pparg y usos de los mismos
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CO2025000035A2 (es) Composiciones farmacéuticas que comprenden inhibidores de helicasa wrn
CL2023003312A1 (es) Inhibidores de nlrp3
MX2020010508A (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados.
CO2023016367A2 (es) Moduladores de trex1
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CL2023000594A1 (es) Compuestos heterocíclicos
CO6300939A2 (es) Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada
CO2022010878A2 (es) Compuestos heterocíclicos novedosos útiles como inhibidores selectivos de aurora a
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX2022004168A (es) Compuestos aromaticos de arilmetileno a manera de bloqueadores del canal de potasio kv1.3.
CL2024002623A1 (es) Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2.
DOP2025000044A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
CL2025001654A1 (es) Compuestos novedosos como moduladores de la inhibición de nlrp3
CL2025002615A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
ECSP23088732A (es) Moduladores de trex1
DOP2011000053A (es) Agentes antifungicos
ECSP23075535A (es) Compuestos cíclicos y métodos de uso